CASI Pharmaceuticals sold its equity interests in Alesta Therapeutics B.V. to BioMarin Pharmaceutical Inc., which acquired Alesta. The transaction closed on August 31, 2026, with CASI receiving approximately US$5.9 million in net cash proceeds and retaining potential rights to contingent milestone payments. Alesta retained its ALE1 asset while spinning out non-ALE1 assets prior to closing, and CASI's licensed rights to CID-103 remain unchanged. CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103 for organ transplant rejection and autoimmune diseases.

CASI Pharmaceuticals reported first-half 2026 revenues of $9.8 million and a net loss of $20.0 million. The company completed a $15 million convertible note financing with ETP Global III Fund LP, controlled by Executive Chairman Dr. Wei-Wu He. Additionally, CASI entered into a settlement agreement with Acrotech Biopharma Inc., rescinding the prior termination of the EVOMELA license and keeping agreements in full force. The company also received a favorable final award in the Juventas arbitration, totaling well over RMB 100 million. Clinically, CASI dosed the first patient in its Phase 1/2 trial for CID-103 in renal allograft antibody-mediated rejection in China and completed enrollment of Part A for its ITP study. The filing notes the company's delisting from Nasdaq and subsequent quotation on OTCQB under ticker CASIF. CASI Pharmaceuticals is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CASI Pharmaceuticals announced that Mr. Wei (Larry) Zhang will no longer serve as Senior Vice President. The departure is part of ongoing efforts to streamline branches, personnel, and related activities in the United States. CASI Pharmaceuticals operates as a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.

CASI Pharmaceuticals, Inc. received a final award from the Hong Kong International Arbitration Centre (HKIAC) in its arbitration proceeding against Juventas Co., Ltd. The tribunal rejected all allegations of breach of agreement by CASI and ruled that Juventas was the wrongful termination of agreements regarding CNCT-19 commercialization. The award includes recovery of wasted costs, interest, HKIAC costs, and legal costs totaling well over RMB 100 million. CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing anti-CD38 monoclonal antibodies for organ transplant rejection and autoimmune diseases.